EEG / EMG

Delsys Inc. is a 30-year-old Massachusetts-based manufacturer of advanced wearable electromyography (EMG) systems and sensors for research, clinical diagnostics, and rehabilitation. The company specializes in wireless, real-time surface EMG technology with proprietary sensor designs and communication protocols optimized for human movement analysis, motor control research, neuromuscular physiology, and neurorehabilitation applications. Their primary product line—Trigno—comprises multiple system configurations (Centro for research-grade applications, Lite for entry-level systems, Link for integrated multimodal data acquisition, and HDsEMG for high-density motor unit analysis). Individual EMG sensors (Avanti, Mini, Duo, Quattro, Snap Lead) and auxiliary modules (Analog Adapter, FSR Adapter, Goniometer, Load Cell, EKG Biofeedback) enable customizable system builds. High-density EMG sensors (Galileo, Maize) support advanced motor unit decomposition and motor control studies. The Trigno ecosystem integrates with external research tools via a documented API and proprietary software (EMGworks, Trigno Discover, NeuroMap). Delsys serves academic institutions, medical research labs, rehabilitation facilities, exoskeleton/wearable robotics developers, and clinical diagnostics centers globally. Products emphasize low-noise signal acquisition, 40+ meter wireless range, intuitive data visualization and analysis workflows, and expandable architecture. The company provides remote and on-site training, technical support, and system integration services.

Replacement Parts Industries, Inc. is a leading distributor of original equipment manufacturer (OEM) replacement parts for hospital, medical, dental, and laboratory equipment. Established in 1972 and ISO 9001 certified, RPI supplies critical spare parts and components for sterilization systems (autoclaves, endoscope washers, sterilizers), laboratory equipment (centrifuges, analyzers), patient monitoring devices (blood pressure monitors, ECG/EKG systems), dental equipment (chairs, delivery systems, handpieces), examination furniture, ventilators, and neonatal care systems. The company serves service technicians, biomedical departments, and hospital procurement teams with an extensive searchable catalog of parts organized by equipment type and manufacturer. RPI offers technical assistance, PM guides, troubleshooting support, and maintains rapid fulfillment from its California distribution center.

LKC Technologies is a specialized medical device manufacturer headquartered in Germantown, Maryland, with over 45 years of expertise in visual electrophysiology. The company designs and manufactures FDA-cleared, portable electroretinography (ERG) and visual evoked potential (VEP) testing systems for both human and veterinary ophthalmology applications. LKC's flagship product, the RETeval®, is a handheld, battery-powered, non-mydriatic ERG/VEP device that enables objective functional assessment of retinal health and visual pathways. The company also offers the UTAS™ mf/PERG system for comprehensive multifocal and pattern ERG/VEP testing, and RETevet™ for veterinary ophthalmology. These devices serve optometrists, ophthalmologists, and research institutions globally, with particular applications in diabetic retinopathy monitoring, glaucoma assessment, inherited retinal disease diagnosis, and pediatric vision evaluation. LKC holds ISO 13485:2016 certification and FDA registration, with products supported by over 250 peer-reviewed publications.

Computational Diagnostics, Inc. (CDI) is a manufacturer of clinical neurophysiology systems and provider of intraoperative neurophysiological monitoring (IOM/IONM) services. Founded in 1988, CDI develops and operates multi-modality neurophysiologic monitoring equipment designed to protect neural structures during surgical procedures. The company's flagship NeuroNet® platform enables real-time neurophysiological data acquisition and remote interpretation by attending neurophysiologists, allowing surgeons to monitor nervous system integrity during complex procedures. CDI offers turnkey IOM services with nationally certified neurotechnologists and neurophysiologists collaborating to deliver immediate clinical feedback. The company also develops telemedicine and home-use neurophysiology systems, supported by research funding from the Army's Telemedicine and Advanced Technology Research Center and the National Institute of Neurological Diseases and Stroke. CDI's technology has received recognition including Computer World/Smithsonian awards.

Ronan Medical is a specialized distributor and leader in qEEG neurofeedback systems and accessories. Founded in 2018, the company focuses on the neurofeedback market, supplying healthcare providers, clinics, and research facilities with advanced quantitative EEG (qEEG) neurofeedback equipment and related accessories. Ronan Medical partners with Deymed to distribute the TruScan qEEG Neurofeedback system—a portable, all-in-one device featuring 24 or 32 channels, high sample rates, continuous online impedance monitoring, and user-friendly interface. The company provides comprehensive sales, training, and technical support for neurotherapy applications, serving the neurofeedback community through both direct distribution and an online store with same-day shipping capabilities for accessories and complementary neurotherapy products.

Jali Medical is a leading U.S. distributor of neuromodulation devices and wearable neurotechnologies, headquartered in Framingham, Massachusetts. Founded in 1991 with over 30 years of experience, the company specializes in non-invasive brain stimulation systems for neuroscience research and clinical applications. Jali Medical distributes FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy systems for treating Major Depressive Disorder, along with advanced electroencephalography (EEG) systems, transcranial direct current stimulation (tDCS/tACS) devices, electromyography (EMG) systems, and neuronavigation equipment. The company serves academic institutions, research centers, hospitals, and clinicians nationwide, providing precision-engineered neurotechnology coupled with comprehensive scientific support. Jali Medical offers flexible leasing options for TMS therapy systems and in-person product demonstrations to facilitate clinical adoption and research innovation in neurophysiology and behavioral health applications.

Med-Dyne is a leading manufacturer of pediatric and adult monitoring solutions based in Louisville, Kentucky. Founded in 1993, the company brings over 30 years of expertise in biofeedback and monitoring technology. Med-Dyne specializes in medical monitoring accessories for ECG, EEG, sleep testing, and infant apnea monitoring applications. The company manufactures a comprehensive range of disposable and reusable electrodes, pre-wired leadwires, cables, and specialized testing supplies with a focus on sensitive skin compatibility. Med-Dyne's patented hydrogel adhesive technology is designed specifically for pediatric patients with delicate skin, offering a firm yet gentle bond with reduced impedance for superior signal quality. The company provides full custom design and packaging capabilities, maintains inventory in stock for rapid fulfillment, and offers same-day shipping. With a central US location and dedicated customer service, Med-Dyne serves healthcare facilities requiring reliable cardiac monitoring, sleep study, and EEG supplies.

Anschel Technology Inc. manufactures the SightSaver™, an FDA-approved and patented device for eliciting visual evoked potentials (VEPs) during intraoperative monitoring. The device is designed to prevent post-operative visual loss (POVL)—a serious complication affecting several thousand patients annually in the United States following non-ocular surgical procedures such as spine surgery. The SightSaver™ addresses critical gaps in existing visual stimulation approaches by providing a hygienic, safe, comfortable, and reliable alternative to low-quality, non-hygienic, and unreliable legacy stimulators. The company was founded in 2011 by Dr. David Anschel, a board-certified neurologist and clinical neurophysiologist with extensive academic credentials and research background. The SightSaver products enable perioperative vision risk management through real-time intraoperative visual monitoring, supporting surgical teams in detecting and mitigating vision loss during high-risk procedures.

Applied Neuroscience develops advanced EEG (electroencephalography) analysis and neurofeedback software platforms for clinicians, researchers, and academic institutions. The company's flagship product, NeuroGuide™, is a comprehensive conventional and quantitative EEG (qEEG) system offering dynamic EEG databases, source localization analysis (swLORETA), coherence mapping, phase analysis, and 3D brain imaging capabilities. NeuroGuide enables real-time EEG visualization with dynamic color maps and automated clinical report generation. The platform supports Z-score neurofeedback protocols with surface, LORETA, and brain-computer interface training modes, including symptom-checklist-driven protocol preparation. NeuroNavigator™ adds current density Z-score mapping for precise functional brain network localization. Additional offerings include automatic clinical report writing integrated with Microsoft Office, expert clinical consultation services, and comprehensive training programs delivered through webinars and workshops. The company serves psychiatrists, neurologists, psychologists, neuropsychologists, and researchers across major universities including Drexel, Stanford, UC San Diego, and Swansea University. Products support conventional and quantitative EEG analysis with advanced metrics including phase locking, phase resetting, cross-frequency analysis, batch processing, and electrophysiological assessment tools.

D.O. Weaver and Company is a leading manufacturer of EEG and ECG electrode preparation and conductive products for cardiac diagnostics, sleep diagnostics, and electroneurodiagnostics applications. Based in Aurora, Colorado, the company specializes in high-performance skin prep gels and conductive pastes designed to reduce impedance and improve signal quality in diagnostic monitoring. Their flagship products—Nuprep Skin Prep Gel and Ten20 Conductive Paste—are trusted by technologists and technicians worldwide for reliable electrode adhesion and conductivity. ISO 13485 certified, Weaver and Company maintains rigorous manufacturing standards and distributes globally through an established distributor network.

BrainScope is a commercial-stage medical neurotechnology company specializing in AI-powered EEG-based diagnostic solutions for brain health. Founded in 2006 and based in Rockville, Maryland, BrainScope has developed a proprietary platform that applies machine learning and computational neuroscience to transform brain electrical activity (EEG) into objective clinical biomarkers. The company created the first FDA-cleared AI/Machine Learning medical device in neurology and holds a portfolio of 83 issued patents. BrainScope's primary offering is a hand-held, point-of-care device for assessing mild traumatic brain injuries (mTBI), structural brain bleeds, and concussions in under 20 minutes. The technology has demonstrated ~50% reduction in unnecessary head CT scans and substantial reductions in emergency department patient length of stay. Beyond head injury assessment, BrainScope is developing novel biomarkers for stroke detection, early Alzheimer's detection (with dementia risk prediction up to 7 years before initial diagnosis), and other CNS indications. The company serves acute care settings, hospitals, emergency departments, and pharmaceutical/drug development partners.

Cogstate Ltd is a neuroscience solutions company specializing in digital cognitive assessment platforms for clinical research and healthcare. Founded in 1999, the company provides validated, computer-based cognitive testing tools designed to measure brain health across connected devices. Cogstate's offerings include digital cognitive assessments, remote assessment capabilities for decentralized clinical trials, endpoint data quality services (rater training and monitoring), and healthcare cognitive screening solutions for clinical care settings. The company supports biopharmaceutical companies and academic institutions in clinical trials across 100+ indications, serving researchers worldwide. With 25 years of expertise, Cogstate has administered over 2 million digital tests and completed 35,800+ rater trainings. The platform is culture-neutral and optimized for precision in pharmaceutical studies, early-phase safety assessments, and cognitive impairment evaluation across conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, and concussion. Cogstate's solutions are applied in neurology, sports medicine, and pharmaceutical development.

BioSignal is a neurodiagnostic company specializing in functional brain assessment via portable EEG technology. The company's FDA-approved microEEG® solution is a miniature, wireless clinical platform enabling rapid electroencephalogram (EEG) recording with cloud-based remote interpretation. BioSignal serves traditional neurology settings (epilepsy centers, sleep labs, neurology departments, ICUs) and expands brain function assessment into novel environments including emergency departments, NICUs, physician offices, ambulances, and home care. The platform supports sports concussion management, traumatic brain injury assessment, routine EEG monitoring, and STAT EEG capabilities. Applications span clinical neurology, emergency medicine, pediatric critical care, sleep medicine, sports medicine, and home sleep monitoring. The solution combines hardware portability with interpretive software to enable rapid assessment and telemedicine-capable EEG interpretation.

Epitel, Inc. is a digital health company based in Salt Lake City, Utah, specializing in innovative wearable EEG monitoring technology for brain health. Founded in 2008, Epitel developed the REMI™ Remote EEG Monitoring System, an FDA-cleared (2021) wireless, wearable sensor platform designed for seizure detection and electrographic monitoring in both hospital and ambulatory settings. The system features single-channel, high-fidelity EEG recordings with rapid setup (minutes), wireless operation enabling patient mobility, and integration with standard EEG review platforms like Persyst™ Mobile for remote clinician review. REMI Vigilenz™ AI for Event Detection augments clinical review by automatically identifying potential electrographic seizure activity with confidence scoring. The platform is clinically validated, reimbursable under existing codes, and suitable for adult and pediatric patients (1+ years for monitoring; 6+ years for AI analysis). Epitel's technology addresses critical care, emergency department, and outpatient epilepsy monitoring needs. The company has secured over $20 million in funding and brings extensive expertise in medical device development, neural engineering, and regulatory affairs.

NeuroMetrix, Inc. is a neurotechnology company specializing in non-invasive medical devices for diagnosing and treating pain and neurological disorders. The company develops point-of-care neuropathy diagnostic tests and FDA-approved wearable neurostimulation devices. Its Quell® platform is a wearable neuromodulator designed for chronic pain management and fibromyalgia symptom reduction. DPNCheck provides rapid nerve conduction testing for peripheral neuropathy evaluation. NeuroMetrix targets healthcare professionals including endocrinologists and podiatrists, as well as direct consumers. Founded in 1996 and based in Woburn, Massachusetts, the company is a wholly-owned subsidiary of electroCore, Inc. and is publicly traded on Nasdaq (NURO). The company emphasizes innovation in digital medicine and neurostimulation through clinical feedback and research.

Alera Medtech is a Boston-based medical device manufacturer specializing in reimagined solutions for neurology and vascular access—two clinical specialties experiencing minimal innovation over three decades. The company develops point-of-care diagnostic tools, monitoring electrodes, and vascular access devices targeting improved signal accuracy, reduced catheter failure rates (currently 40–50%), and enhanced clinical workflow efficiency. Core products include DPNCheck®, an FDA-cleared quantitative nerve conduction test for diabetic peripheral neuropathy screening; Cernode™ medical electrodes; and SureSet™ catheter securement systems. Alera combines modern materials engineering with clinician-centered design to deliver cost-effective solutions accessible to primary care, endocrinology, neurology, and hospital systems globally, with manufacturing in Buckley, WA, and offices in the Middle East and Asia.

Cognision, operating as Neuronetrix Solutions, LLC, is an FDA-cleared medical technology company specializing in advanced EEG/ERP systems for objective evaluation of cognitive function. Founded in 2003, the company develops brain-based biomarker solutions for clinical assessment and pharmaceutical research. The COGNISION® System features a user-friendly EEG/ERP device with a comfortable headset for point-of-care testing, generating intuitive clinical reports. The technology is validated for assessing concussion, mild traumatic brain injury (mTBI), dementia, Alzheimer's disease, and other cognitive disorders. Cognision serves healthcare systems, private practices, universities, and global clinical trial sponsors, providing objective physiological measures of cognitive function for clinicians, researchers, and pharmaceutical companies conducting CNS drug development studies.

Ad-Tech Medical Instrument Corporation is the world leader in electrode devices for neurological diagnostics and therapeutic applications. The company specializes in long-term EEG monitoring, brain mapping, stereoelectroencephalography (SEEG), and brain stimulation, primarily for surgical evaluation and treatment of intractable epilepsy and other neurological disorders. Ad-Tech's proprietary product portfolio includes subdural strip and grid electrodes, dual-sided subdural electrodes, depth electrodes with micro contacts, foramen ovale electrodes, intraoperative electrodes, spinal electrodes, electrode placement kits, accessory placement devices, and brain biopsy needles. The company is known for field-proven designs incorporating advanced materials and components, with emphasis on ease of use and proprietary connection systems. Devices are indicated for long-term monitoring up to 29 days. Ad-Tech was acquired by Nihon Kohden in a strategic move to strengthen comprehensive epilepsy diagnostics and care capabilities. The company serves surgeons, specialists, researchers, and neurosurgical centers globally, primarily through distributor networks. Founded in 1985, Ad-Tech maintains manufacturing and distribution operations from its Wisconsin headquarters.

Omniscient Neurotechnology develops AI-powered connectomic analysis software for precision brain mapping and surgical planning. The company specializes in digital brain mapping technology that generates personalized connectomes—computational maps of brain functional and structural connections—using advanced algorithms and cloud-based processing of MRI and resting-state functional MRI (rs-fMRI) data. Quicktome is their flagship platform, an automated connectomic analysis solution designed for neurosurgeons and researchers to extract actionable insights into patient-specific brain networks prior to surgery and for large-scale neural data processing in research settings. The platform supports clinical decision-making across neurologic conditions including cranial surgery, neuro-oncology, depression, Alzheimer's disease, schizophrenia, and stroke. By automating what historically required manual tractography and reducing processing time from hours to under 2 hours with minimal clinician intervention, Quicktome enables faster surgical planning while preserving critical functional brain regions. The company operates through global distribution partnerships and maintains offices in Australia (Sydney, NSW) and the United States (Atlanta). Omniscient holds SOC 2 compliance certification and patents issued by the USPTO. The technology is positioned at the intersection of neuroimaging, artificial intelligence, and cloud computing, serving both clinical and research institutions worldwide.

FHC, Inc. is a specialized medical device manufacturer based in Bowdoin, Maine, founded in 1970. The company focuses on neuroscience and neurosurgery solutions, particularly cranial microtargeting and neuromodulation. FHC designs and manufactures microelectrodes, electrode positioning systems, stereotactic platforms, and surgical planning software for both clinical and research applications. Their clinical product line includes the Guideline 5 Neuromodulation System, STarFix Stereotactic Platforms, STar Microdrive System, and WayPoint Navigation software for surgical planning. The research division offers NeuroCraft microelectrodes and insertion tubes for neurophysiology studies. FHC's solutions support therapeutic interventions including deep brain stimulation, ablation, resection, and treatment of movement disorders such as Parkinson's Disease, epilepsy, dystonia, and essential tremor. The company also provides stereoelectroencephalography (SEEG) equipment and operates Greenville Neuromodulation Services for DBS research and surgeon training. With approximately 170 employees and estimated annual revenue of $42.6 million, FHC serves neurosurgical centers and research institutions globally.

Alacer Bio is a medical equipment manufacturer specializing in diagnostic and therapeutic systems for gastroenterology, urology, and pelvic physiotherapy. The company designs and supplies equipment, software, and accessories for specialized clinical examinations including high-resolution esophageal manometry, anorectal manometry, impedance-pH monitoring, uroflowmetry, urodynamics, video urodynamics, and pelvic floor electromyography biofeedback. Products comply with International Continence Society (ICS) regulations for urodynamic studies. Alacer maintains over 20 years of experience in medical training delivery across clinical settings and laboratory environments. Service offerings include webinars, live online training, recorded training videos, and face-to-face instruction. The company provides comprehensive post-sale technical support and customer service. Geographic reach includes Brazil, Argentina, and Spanish-speaking markets, with a growing US presence. All product systems integrate software for data acquisition, analysis, and clinical reporting tailored to functional diagnostic and therapeutic protocols.

Mind Media Group manufactures and supplies EEG-based neurotechnology platforms for clinical, research, and educational applications. The company's core product line is the NeXus system—a multimodal biosensor platform available in wireless configurations (NeXus 10 MK3, NeXus Q24, NeXus Q32)—designed for nervous system sensing and real-time biofeedback/neurofeedback training. NeXus integrates EEG acquisition with sensors for physiological measurement (heart rate variability, skin conductance, respiration) and connects to Biotrace+, proprietary software for quantitative EEG (qEEG), biofeedback protocols, and neurofeedback applications. The platform serves three primary markets: clinical practice (mind-body assessments, therapeutic training for PTSD, ADHD, anxiety, depression), research (3000+ peer-reviewed publications), and education (certification and practitioner development). Complementary offerings include EEG caps, sensors, and cables. The company is widely adopted by major medical centers (Mayo Clinic, Cleveland Clinic, Kaiser Permanente), military and VA health systems (Walter Reed, multiple VA facilities, Department of Defense), academic institutions (MIT, Harvard, Max Planck Institute), and specialized centers (Rady Children's Hospital, Schön Klinik). Mind Media provides comprehensive training and education through its Path to Mastery Academy, offering courses from biofeedback basics through certified practitioner certification. The platform supports clinical assessment, performance optimization, and neuroscience research. Regulatory status, ISO certifications, and FDA classification status are not explicitly stated in available content.

Max Neuro Supply Inc. is a distributor and supplier of electroneurodiagnostic (END) accessories and electrodes for EEG and EMG applications. The company sources products from Xi'an Friendship Medical Electronics Co., Ltd., a high-tech multinational manufacturer specializing in disposable neurological diagnostic electrodes and nerve stimulation probes. Product portfolio includes disposable subdermal needle electrodes (corkscrew and concentric designs), disposable pre-gelled silver/silver chloride (Ag/AgCl) surface electrodes, EEG cup electrodes (gold and Ag/AgCl variants), and nerve stimulator probes in multiple configurations (double hook, triple hook, bipolar, monopolar, ball-tip, and flush-tip designs). These accessories are essential consumables for clinical neurophysiology labs, hospitals, and diagnostic facilities performing electroencephalography, electromyography, and intraoperative neuromonitoring. The company emphasizes low-cost, high-quality disposable solutions for routine diagnostic and monitoring procedures. Products appear to meet international standards for medical device manufacturing and distribution, though specific certifications are not detailed on the site.

Advanced Brain Monitoring, Inc. is a neuro-diagnostics device company specializing in EEG-based technologies for clinical assessment, research, and sleep medicine applications. The company manufactures a portfolio of portable and in-home diagnostic and therapeutic devices targeting clinicians, researchers, and clinical trial sponsors. Product lines include Sleep Profiler and Sleep Profiler PSG2 (Type 2 home sleep apnea testing devices), STAT X-Series and B-Alert X-Series (mobile EEG systems for on-call, portable, and operational neuroscience applications), Night Shift (positional therapy device for obstructive sleep apnea), Apnea Guard (temporary oral appliance for OSA treatment), and PoSAS (Positional Sleep Assessment System software for sleep phenotyping and efficacy evaluation). The company offers clinical trial services for pharmaceutical and medical device sponsors, including EEG-based awake and asleep assessments, and research support services including protocol design, system integration, data analysis, and grant proposal assistance. Applications span sleep medicine, neurodegenerative disease monitoring (Alzheimer's, dementia), cognitive assessment, epilepsy monitoring, PTSD evaluation, fatigue management, brain-computer interface research, and neuropsychiatry evaluation. The company serves hospital and medical centers, university and research institutions, government and military organizations, clinical sleep centers, and product development partners. Located in Carlsbad, California, ABM maintains an international presence with peer-reviewed publications in cognitive neuroscience and clinical applications.

NeuroField Neurotherapy is a clinical neurotherapy provider specializing in brain mapping, neurofeedback, and advanced neuromodulation treatments. Located in Santa Barbara, California, the clinic uses quantitative EEG (QEEG) brain mapping to assess neurological function and designs personalized treatment protocols integrating transcranial alternating current stimulation (tACS), transcranial direct current stimulation (tDCS), pulsed electromagnetic field stimulation (pEMF), vagal nerve stimulation (tVNS), photobiomodulation (PBM), and noise-based stimulation modalities. Led by PhD-credentialed clinicians (Dr. Tiff Thompson, MFT, QEEG-D; Dr. Nicholas Dogris, PhD, BCN, QEEG-DL), the practice treats conditions including PTSD, depression, anxiety, ADHD, autism, sleep disorders, traumatic brain injury, and cognitive decline. The clinic combines neurostimulation with psychotherapy and complementary therapies such as cranio-sacral alignment and hyperbaric oxygen therapy. NeuroField also operates the School of Neurotherapy, an educational platform training clinicians in neurotherapy methodologies and QEEG analysis.

MGC Diagnostics Corporation is a global medical technology company specializing in non-invasive cardiorespiratory diagnostic products and systems. Founded in 1986 and headquartered in Saint Paul, Minnesota, the company designs and manufactures advanced diagnostic equipment for measuring respiratory function, gas exchange, and cardiovascular performance. Key product lines include pulmonary function testing systems, cardiopulmonary exercise testing (CPET/CPX) equipment, FeNO (fractional exhaled nitric oxide) monitoring systems, indirect calorimetry devices, stress testing systems, and treadmills. The company serves hospitals, clinics, sports medicine facilities, and pulmonary rehabilitation centers with integrated solutions for disease detection, chronic disease monitoring, and patient wellness across cardiorespiratory health. MGC Diagnostics provides comprehensive support including technical assistance, training programs, clinical research solutions, and preventive maintenance services.

Medricks is a medical device accessory supplier specializing in patient monitoring cables, lead wires, and associated consumables. With over 40 years of industry experience, the company provides ECG/EKG lead wires (reusable and disposable), trunk cables, SpO2 sensors, NIBP (non-invasive blood pressure) cuffs and connectors, and neuro monitoring accessories. Medricks sources from multiple established vendors and manufactures custom-configured products to meet facility-specific requirements. The company serves hospitals, clinics, and healthcare facilities requiring replacement and spare monitoring accessories. Product portfolio includes both standard off-the-shelf items and contract-manufactured solutions. Medricks accommodates GPO contracts, volume pricing, and bulk orders. The company maintains a B2B e-commerce platform for direct ordering and offers responsive customer support.

machineMD AG is a medical device company founded at the University Hospital of Bern, Switzerland, specializing in non-invasive neuroophthalmological diagnostic equipment. The company develops neos®, a proprietary neurophthalmoscope platform designed for automated, quantitative assessment of eye movements, pupils, and visual fields. neos® enables standardized, objective measurement of neuroophthalmological function across primary, secondary, and tertiary care settings, reducing operator variability and extending specialist-level diagnostic capability to underserved clinical environments. The platform incorporates quantitative pupillometry and oculometric analysis with demonstrated clinical applications across neurological and ophthalmological indications including multiple sclerosis, myasthenia gravis, Parkinson's disease, Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, age-related macular degeneration, and other neurodegenerative and neuro-ophthalmological conditions. machineMD operates facilities in Bern, Switzerland (headquarters at Weyermannsstrasse 36, 3008 Bern) and Cambridge, Massachusetts (1 Broadway, Cambridge, MA 02142). The company maintains active clinical partnerships with major Swiss academic hospitals including University Hospital Lucerne (LUKS), Inselspital Bern, and Universitätsspital Zürich, and international collaborations. Regulatory pathway and specific FDA/CE certification status not detailed on accessible site content.

MEGIN is a global leader in magnetoencephalography (MEG) technology for functional neuroimaging. The company develops integrated solutions for clinical neurology, neurosurgery, and research applications. MEGIN's flagship product is MEG Maps™, powered by TRIUX™ neo hardware and MEG review™ software, providing seamless acquisition, database management, and analysis capabilities for presurgical evaluation and brain mapping. MEG (magnetoencephalography) is a non-invasive, real-time functional brain imaging modality that detects the small magnetic fields generated by active brain cells. MEGIN's technology localizes brain function to within centimeters or millimeters, identifying normal and abnormal activity without applied magnetic fields, radiation, or injections. The system is unaffected by skull and scalp, complementing hemodynamic data from MRI and other modalities (fMRI, PET, SPECT, TMS). Key clinical applications include presurgical evaluation and surgical planning for epilepsy, brain tumors, and neurological disorders; intracranial EEG (iEEG) placement guidance; and research in epilepsy, traumatic brain injury, PTSD, stroke, dementias, and Parkinson's disease. MEG is used in Phase I and III pharmaceutical drug development for neural mechanism assessment. Installed systems serve leading hospitals and research institutions worldwide, including Mayo Clinic, Boston Children's Hospital, Amsterdam UMC, University of Cambridge, and Swinburne University. MEGIN maintains headquarters in Espoo, Finland, with production facilities in Helsinki, and regional offices in the UK and Japan.

LifeSync is a vertically-integrated manufacturer and direct supplier of cardiac cables, leadwires, and neuromonitoring connections for patient monitoring and diagnostic applications. The company specializes in ECG/cardiac monitoring cables, EMG electrodes for muscle and nerve testing, EEG electrodes for brain monitoring, intraoperative neuromonitoring (IONM) tools, nerve conduction study (NCS) supplies, and polysomnography (PSG) accessories. LifeSync positions itself as a single-source alternative to expensive OEM connections from multiple suppliers, emphasizing cost-effectiveness without compromising signal quality and radiolucency. The company manufactures radiolucent leadwires designed to provide clear signal and unobstructed imaging views during diagnostic procedures. LifeSync also offers custom design, manufacturing, and fulfillment services for medical cables and connections through its contract manufacturing division. The company maintains vertical integration across product design, manufacturing, and customer service. Leadership includes executives with 20+ years of experience in medical device development and operations at companies including Johnson & Johnson, GE Healthcare, Philips Healthcare, and 3M Healthcare. LifeSync serves global healthcare providers, hospital systems, and medical device manufacturers. The company operates from Coral Springs, Florida, with same-day shipping available on orders placed by 2 PM EST.

ANT Neuro is a global neurotechnology company specializing in EEG (electroencephalography) systems, neuronavigation solutions, and neurofeedback platforms for clinical diagnostics and neuroscience research. The company manufactures and distributes high-density EEG amplifiers (eego™ product line), EEG caps and electrodes, and the visor2™ navigated transcranial magnetic stimulation (TMS) system, which is FDA 510(k)-cleared. Their solutions serve neurologists, neuroscientists, psychiatrists, and research institutions worldwide. ANT Neuro operates through regional distribution centers in the Netherlands, Germany, UK, Asia-Pacific, North America, and Australia, with local sales and application support teams. The company maintains CE and MDR compliance for medical devices and hosts the international ANT Neuromeeting conference annually, underscoring their commitment to advancing clinical and research neurotechnology. Products address functional diagnostics including EEG/EMG applications in sleep studies, epilepsy monitoring, and brain-computer interface research.

Natus Medical Incorporated is a leading provider of neurodiagnostic and sensory assessment solutions serving hospitals, clinics, and research facilities. The company specializes in electroencephalography (EEG), electromyography (EMG), nerve conduction studies (NCS), and evoked potential (EP) technologies for diagnosing and monitoring brain, nerve, and muscle disorders. Core product portfolio includes the UltraPro S100 EMG/NCS/EP system, NeuroWorks EEG software for routine, ambulatory, and ICU monitoring, and BrainWatch, a wireless point-of-care EEG platform for emergency and intensive care settings. Additionally, Natus operates a separate sensory division (natussensory.com) offering hearing and balance assessment, vision screening, and newborn care solutions. With over 80 years of industry experience, the company delivers integrated hardware, software, and data management platforms alongside comprehensive service, support, and clinical education through Natus Academies. Products are designed with clinician input to streamline workflows in routine EEG, long-term monitoring, ICU applications, and research studies. The organization positions itself as a comprehensive neurodiagnostic partner, supporting screening, diagnosis, treatment, and management of neurological and sensory conditions across care settings.

Epiminder Limited develops and commercializes Minder®, an FDA-authorized implantable continuous EEG monitoring (iCEM®) system for long-term brain activity surveillance. The Minder system is designed to address diagnostic and management challenges in drug-resistant epilepsy by enabling continuous neural monitoring over months to years, compared to traditional scalp EEG monitoring limited to days. The implantable device allows patients to maintain normal daily activities while collecting high-quality EEG data, with remote monitoring capabilities to support clinical assessment and treatment planning. Epiminder targets neurologists and epilepsy centers managing patients with drug-resistant epilepsy, representing approximately 1.1 million adults in the US alone. The company emphasizes evidence-based innovation, clinical validation, and collaboration with the global epilepsy care community. Minder represents a significant advancement in seizure detection and neurological monitoring, extending the diagnostic window and providing actionable data to guide therapeutic interventions.

Vistim Labs develops Ceregram, a patented Evoked Potential Tomography (EPT) technology for non-invasive, radiation-free neurological monitoring. The platform is designed to track disease progression in dementia patients (Alzheimer's, Parkinson's, Lewy Body Disease) and other neurological disorders by localizing and quantifying sensory deficits caused by neurodegeneration. Ceregram monitors across multiple disease endpoints including brain volume changes, physiological markers (amyloid and tau accumulation), and psychological/cognitive performance metrics (MMSE, CERAD, TASIT). The technology enables point-of-care evaluation in office-based clinical settings, allowing physicians to assess treatment response and adjust disease management in real time without requiring PET imaging or other advanced neuroimaging. The company has published peer-reviewed research in Alzheimer's Research and Therapy Journal and presented findings at major conferences including the American Academy of Neurology (2025) and Alzheimer's Association International Conference (2023). Ceregram is positioned as a clinical decision-support tool for cognitive monitoring and is not intended as a diagnostic device or replacement for PET, MRI, or other imaging modalities. The company operates with offices in Miami and San Diego, with affiliate locations in New York, Paris, and Berlin. Vistim Labs has participated in biotech accelerators (PharmStars, Boston) and won multiple startup pitch competitions.

Cognivue manufactures FDA-cleared digital cognitive assessment devices for early detection of cognitive impairment. The company's proprietary adaptive psychophysics technology collects 130,000 data points per assessment, delivering self-administered computerized evaluations customized to each patient's visual and motor skills. The platform removes bias inherent in traditional cognitive assessment tools and provides standardized testing across diverse healthcare settings. Cognivue offers two primary product lines: Cognivue Clarity®, a 10-minute comprehensive assessment evaluating four cognitive domains (memory, executive function/attention, discrimination, visuospatial) plus two performance parameters; and Cognivue Thrive®, a 5-minute abbreviated screening tool assessing three cognitive domains (memory, visuospatial, executive function). Both devices are validated against gold-standard assessment tools such as Montreal Cognitive Assessment (MoCA) and St. Louis University Mental Status (SLUMS) examination, demonstrating superior test-retest reliability and high sensitivity for detecting mild cognitive impairment. The company markets its assessment platform to physicians, hearing healthcare providers, and pharmacies. Clinical data demonstrates Cognivue's effectiveness as an adjunctive tool for cognitive function evaluation in primary care, geriatric, audiology, and pharmacy settings. Cognivue also offers Cogniwell®, a patient-facing lifestyle program complementing clinical assessment. The devices are indicated as adjunctive tools and require licensed clinician interpretation; they do not function as standalone diagnostic instruments. Cognivue is headquartered in Victor, NY, and maintains FDA 510(k) clearance for its technology platform.

Gereonics Inc. manufactures specialized biomedical sensors and electrodes for diagnostic and research applications. The company specializes in EEG (electroencephalography) electrodes and systems, including their proprietary Free-Cap EEG Net for non-invasive brain activity monitoring. Product portfolio includes biopotential electrodes for multi-channel physiological signal acquisition and piezoelectric respiratory sensors featuring low-cost, low-profile beltless/adhesive designs using PVDF technology. These sensors are used in sleep studies, clinical diagnostics, and research settings. The company serves hospitals, sleep laboratories, research institutions, and clinical facilities requiring portable and reliable signal acquisition devices. Manufacturing capabilities include custom electrode designs and respiratory sensor configurations. Gereonics operates as a US-based medical device supplier with distribution to clinical and research markets. Products are designed for ease of use, patient comfort, and accurate signal fidelity in demanding diagnostic environments.

QuantalX Neuroscience manufactures Delphi-MD™, a non-invasive brain network function assessment device using Direct Electrophysiological Imaging technology to map real-time brain activity. The device captures transcranial magnetic stimulation (TMS)-evoked brain potentials (TEPs) and provides quantitative output parameters compared against a normative reference database for ages 50–75. Unlike conventional neuroimaging, Delphi-MD™ operates in any care setting—clinics, hospitals, research facilities—without radiation exposure. The system is indicated for brain health assessment, neurology, psychiatry, and research applications. FDA De Novo cleared, the device generates comprehensive, age-correlated results reports integrated into clinical workflows. Key features include rapid assessment, radiation-free operation, proven validation through peer-reviewed publications, and cost-effectiveness. Clinical interpretations must be made by qualified healthcare professionals within full patient evaluation context. Potential adverse events include headache, nausea, dizziness, fatigue, insomnia, anxiety, back/neck pain, vomiting, tinnitus, migraine aura, and abnormal sensations. The device is not intended as a sole diagnostic tool. Serves providers, researchers, and institutional buyers seeking objective, accessible brain function measurement.

Carrier Medical, LLC is a leading distributor of medical equipment and solutions serving VA and DOD hospitals nationwide. The company specializes in providing high-quality medical devices across multiple specialties including neurology, sleep diagnostics, physical medicine and rehabilitation, respiratory care, and CPAP comfort products. Product lines include CPAP mask liners and headgear comfort covers made from bamboo organic fabric (Cloud brand); mobility and assistive devices such as rollators, knee walkers, transport chairs, and canes (PerfectFit, Phantom, Nova brands); and sleep diagnostic consumables including EEG electrodes and complete sensor kits (Dymedix brand). The company operates an e-commerce platform offering direct purchasing with nationwide fast shipping. Carrier Medical serves both institutional and individual customers, with documented experience supplying hospital inventory for multi-year partnerships. Products emphasize comfort, durability, and quality construction with features such as machine-washable liners and heavy-duty weight capacities. The company maintains customer support infrastructure and satisfaction guarantees.

BrainCheck is a software platform for cognitive assessment and care planning, headquartered in Austin, Texas with operations in New York City. The company develops FDA-registered Class II digital cognitive assessment tools designed to integrate into clinical workflows for neurologists, psychiatrists, primary care providers, and clinical researchers. BrainCheck Assess, the platform's flagship product, is a 15-minute cognitive evaluation spanning five domains that detects subtle signs of cognitive impairment, potentially associated with dementias including Alzheimer's disease. The platform comprises 30+ clinical evaluation tools including validated screeners, assessments, and surveys. Published peer-reviewed research demonstrates that BrainCheck Assess scores correlate highly with the Montreal Cognitive Assessment (MoCA, r=0.77) and can distinguish between normal cognition, mild cognitive impairment, and dementia with high sensitivity and specificity. The platform supports seamless integration with major electronic health record systems (Epic, athenahealth) to enable cognitive screening, assessment, interpretation, care planning, and follow-up within routine care. BrainCheck's clinical validation is supported by a normative database of 5,000+ patients and real-world data from 450,000+ patient assessments. The company collaborates with leading academic and research institutions including University of Texas at Austin, Johns Hopkins University, Mount Sinai, Stanford University, and MD Anderson Cancer Center. U.S.-based clinical and technical support is available for product use, documentation, and billing inquiries.

Intelligent Hearing Systems manufactures portable audiology and evoked response testing systems for clinical screening, diagnostics, and research applications. Established in 1983, the company specializes in portable platforms for ABR (Auditory Brainstem Response), OAE (Otoacoustic Emissions), ASSR (Auditory Steady-State Response), and VEMP (Vestibular Evoked Myogenic Potential) testing. Their product portfolio includes the SmartScreener-Plus 2 for cost-effective infant hearing screening, the Duet and Aria clinical EP systems with optional OAE capabilities, and the Solo compact ABR/ASSR platform. IHS also offers advanced research modules (SmartEP AARM), high-frequency transducers, vestibular assessment tools (SmartVEMP), and training simulation software including the Baby ISAO simulator. The company emphasizes integrated, portable solutions with comprehensive data management and multi-language support for audiological and balance assessment in clinical, screening, and research environments.

Spryson (formerly Neurolign Technologies) is a world leader in neuro-functional monitoring and AI-driven eye-tracking diagnostics. The company specializes in non-invasive neurological assessment technology designed to detect and monitor neurodegenerative diseases, with particular focus on Parkinson's disease and traumatic brain injury/concussion detection. NeuroAI is their flagship platform that combines advanced eye-tracking with proprietary biomarkers and predictive analytics to enable earlier diagnosis, progression monitoring, and treatment optimization. The company has applied for FDA Breakthrough Device Status for their PD-Check technology. Spryson's approach emphasizes accessibility, bringing sophisticated neurological diagnostic capabilities to clinical institutions, research organizations, and consumer wellness applications. Their technology captures subtle neurological markers—including oculomotor responses, vestibular function, reaction time, and cognitive measures—that traditional assessment methods miss, delivering real-time objective data to clinicians for enhanced diagnostic accuracy and decision support.

BIOPAC Systems, Inc. designs and manufactures modular, integrated life science data acquisition and analysis systems for research, education, and human insights applications. The company specializes in high-fidelity measurement of physiological signals including electrocardiography (ECG), electroencephalography (EEG), electromyography (EMG), electrodermal activity (EDA), blood pressure, impedance cardiography, and specialized measures such as functional near-infrared spectroscopy (fNIRS) and laser Doppler flow. BIOPAC systems operate in laboratory, MRI, and real-world/field environments with both wired and wireless data logging capabilities. The company serves three primary markets: academic research (human and animal studies, neuroscience, cardiology, psychophysiology), educational institutions (undergraduate and graduate teaching labs across multiple disciplines), and commercial/human insights applications (consumer research, neuromarketing, product development). Products include the AcqKnowledge software platform for data acquisition and analysis, modular hardware units, and the Biopac Student Lab System with integrated curriculum. Systems support advanced signal processing including heart rate variability analysis, automated ECG/EEG/EMG analysis, event-related potentials (ERP), and cognitive state assessment. BIOPAC is cited in over 58,600 peer-reviewed studies. The company provides extensive support through technical specialists, knowledge bases, application notes, webinars, hands-on workshops, and user manuals for both proprietary and third-party hardware integration.

NeuroOne Medical Technologies develops minimally invasive diagnostic and therapeutic neurosurgical devices based on proprietary thin-film electrode technology. The company's primary platform enables high-definition neuronal recording and ablation for functional neurosurgery, with an initial focus on epilepsy and trigeminal neuralgia treatment. Core products include the OneRF® Radiofrequency Ablation System (FDA-cleared K231675 for functional neurosurgical procedures; K251243 for trigeminal nerve ablation), which uniquely performs both diagnostic mapping and therapeutic ablation using the same stereotactic electroencephalography (sEEG) electrode. The Evo® sEEG System (FDA-cleared K222404) provides temporary subsurface brain recording, monitoring, and stimulation, while the Evo® Cortical Electrodes (FDA-cleared K192764) offer surface brain recording with reduced immunological response and improved cable management. NeuroOne's flexible thin-film electrode platform is designed to provide higher-resolution neural signal acquisition compared to conventional rigid electrodes, potentially reducing infection risk and procedure complexity. The company is developing a comprehensive portfolio for neurological applications beyond epilepsy, working with leading neurosurgical centers including Mayo Clinic. All devices are subject to federal restriction to sale by or on the order of a physician.

Neurovirtual USA, Inc. is a global manufacturer of neurology and sleep medicine diagnostic equipment. The company specializes in advanced diagnostic systems for sleep medicine, neurology, and related clinical applications. Their product portfolio includes sleep study systems, EEG/EMG equipment, and ambulatory EEG monitoring solutions. Neurovirtual positions itself as a fast-growing provider committed to offering advanced diagnostic equipment at competitive pricing without compromising quality. The company serves healthcare facilities requiring neurology and sleep medicine diagnostic capabilities, with demonstrated presence at major medical conferences including SBNC (Sleep and Brain Disorders Conference) and epilepsy educational events. Manufacturing and distribution operate on a global scale. While specific regulatory certifications are not explicitly detailed in available marketing materials, the company's participation in professional medical conferences and focus on clinical diagnostics suggests compliance with relevant medical device standards.

BIO PROTECH, INC. is a medical device manufacturer specializing in surgical instrumentation, patient monitoring electrodes, and therapeutic devices for intraoperative and diagnostic applications. The company produces surgical smoke evacuation systems including smoke pencils (telescopic, economy, dual extension), surgical pencils, smoke adapters, and laparoscopic accessories, along with electrosurgical unit (ESU) plates. In cardiology, BIO PROTECH manufactures ECG electrodes, TAB electrodes, neonatal electrodes, and SpO2 sensors for patient monitoring. The neurology product line includes EMG needles and electrodes, EEG cup electrodes, surface electrodes, intraoperative neuromonitoring (IONM) needles, and neurology cables. Pain management offerings encompass TENS (transcutaneous electrical nerve stimulation) electrodes and TENS units, as well as EMS (electrical muscle stimulation) and interferential (IF) therapy units. The company serves global markets with manufacturing and distribution capabilities, operating sales offices in both North America (Cerritos, CA) and South Korea, with support for Europe, Middle East, Asia, South America, Oceania, and Africa. Products are designed to meet global quality standards for surgical, diagnostic, and therapeutic applications across multiple medical specialties.

DIXI Medical is a specialized neurosurgical device manufacturer with over 50 years of expertise in stereotactic electroencephalography (SEEG) systems and functional neurosurgery. The company develops high-precision intracerebral electrodes, intraoperative neurophysiological monitoring systems, and stereotactic implantation accessories for epilepsy diagnosis, treatment, and brain research applications. Core product lines include MICRODEEP® SEEG electrodes (sterile, single-use with up to 18 contacts and 0.8 mm diameter for deep brain exploration and thermocoagulation), MICRODEEP® Micro-Macro electrodes (for simultaneous multi-scale neuronal recording bridging clinical and research use), and Cortical IOM electrodes for intraoperative real-time cortical monitoring and stimulation. The company also manufactures dedicated stereotactic implantation instruments and accessories. DIXI Medical serves epilepsy centers and functional neurosurgery programs in over 40 countries and supports SEEG training and research initiatives globally. Manufacturing capabilities include microtechnical precision engineering, sterilization, and quality assurance aligned with medical device standards. The company emphasizes clinical collaboration with neurosurgeons, neurologists, and researchers, with field-based clinical support teams and ongoing investment in training programs for healthcare professionals. Products are designed for compatibility with robotic stereotactic systems and are used in both surgical and research settings.

Head Diagnostics Ltd is an Irish medtech company specializing in clinically validated AI-driven digital solutions for neurological assessment and brain health management. The company develops cloud-based software platforms and handheld medical devices focused on cognitive assessment, neuropsychological testing, and brainstem function evaluation. Primary product: HDx Cognition (formerly IntelliSpace Cognition, originally developed by Philips) is a cloud-based Software-as-a-Service platform for comprehensive, digitized neuropsychological assessment across six cognitive domains. The platform comprises a patient tablet interface and clinician PC/tablet interface, delivering immediate scoring, normative comparisons, and automated reporting. Assessments align with established neuropsychological measures and have been clinically validated through multiple U.S. clinical trials on demographically representative populations. Secondary product: iTremor is a handheld, non-invasive device using laser speckle metrology to measure Ocular Microtremor (OMT) as an indicator of brainstem function. It delivers objective neurological insights in three seconds; currently restricted to research use (not FDA cleared). The company targets clinical workflows in neurology, geriatrics, and memory clinics, supporting assessment and monitoring of mild cognitive impairment, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, and traumatic brain injury. HDx Cognition is normed on large U.S. populations and demonstrates reliability and equivalence to traditional paper-based testing. The platform integrates with electronic health records and enables longitudinal patient monitoring and remote assessment with clinician oversight. Certifications and recognition: Red Dot Award (2020), iF Design Award (2020), UX Design Award (2020), 2023 AI in Healthcare Award, 2024 Irish Medtech Awards finalist, and George Sigerson Award (2024). Technology is grounded in decades of cognitive science research and developed in collaboration with leading clinicians, hospitals, universities, and research centers.

Alpha Omega Engineering Ltd. is a specialized neuroscience and neurosurgery technology company developing advanced systems for neurophysiology research, deep brain stimulation (DBS) procedures, and clinical applications. The company manufactures microelectrode recording (MER) systems, brain mapping software, and DBS navigation tools used in human, primate, and rodent research settings, as well as in clinical neurosurgery and functional neurology. Their product portfolio includes portable and stationary MER systems with target localization capabilities, motorized commutators for free-moving animal studies, and neurological patient management platforms. Alpha Omega serves research institutions, neurosurgical centers, and clinical research organizations globally, supporting thousands of DBS procedures annually. The company emphasizes engineering precision, data reliability, and repeatability in neurophysiological signal acquisition. Their clinical research solutions integrate sophisticated hardware and software for brain mapping in both awake and asleep DBS procedures for the treatment of movement disorders and psychiatric conditions. Alpha Omega provides comprehensive customer support, technical engineering assistance, and training to optimize system implementation and clinical outcomes.

Cumulus Neuroscience develops NeuLogiq®, a medical-grade, at-home digital data collection and analytics platform for functional brain health monitoring and central nervous system (CNS) disease management. The platform combines a 510(k)-cleared novel EEG headset with tablet-based cognitive, mood, language, and sleep assessments, synced to cloud-based machine learning analytics. NeuLogiq enables frequent longitudinal monitoring in clinical and home settings, designed to address challenges in CNS drug discovery including late diagnosis, patient stratification, and treatment monitoring. The company serves pharmaceutical companies conducting clinical trials through its Cumulus Pharma Advisory Group (CPAG), a paid-in consortium that includes ten major global pharmaceutical companies: Biogen, GSK, Pfizer, Eli Lilly, Takeda, Bristol Myers Squibb, Boehringer Ingelheim, Merck, Roche, and J&J Innovative Medicine. Several CPAG members have active studies using the NeuLogiq Platform. The platform assesses discrete brain functions including working memory, episodic memory, executive function, decision-making, neuronal integrity, network connectivity, emotional bias, speech characteristics, and sleep metrics. The company employs approximately 30 engineers, scientists, and business professionals, backed by experienced life science and technology investors including the Dementia Discovery Fund, as well as UK and EU innovation agencies. Regulatory clearance includes FDA 510(k) for the EEG headset. NeuLogiq integrates third-party validated algorithms for facial expression recognition, language analysis, and sleep staging.

MEGIN Oy is a global leader in magnetoencephalography (MEG) technology for functional neuroimaging. The company develops and markets MEG Maps™, an integrated end-to-end solution powered by TRIUX™ neo hardware and MEG review™ software, designed for presurgical evaluation, clinical neurology, neurosurgery, and neuroscience research. MEG technology detects small magnetic fields generated by active brain cells, enabling real-time, non-invasive localization of brain activity to within centimeters or millimeters. MEGIN's systems are non-invasive, silent, radiation-free, and unaffected by skull properties or hemodynamic confounds, offering advantages over traditional fMRI and other functional imaging modalities. The TRIUX™ neo represents an advanced acquisition system with improved signal-to-noise ratios and advanced signal analysis capabilities. MEG Maps™ integrates scan acquisition, database management, and analysis functionality for clinical workflows. The company's solutions are deployed in hospitals and research institutions worldwide, including Mayo Clinic, Amsterdam UMC, Boys Town National Research Hospital, and major research centers. Applications include presurgical mapping for epilepsy and tumor surgery, epilepsy diagnosis and monitoring, brain tumor assessment, traumatic brain injury evaluation, stroke research, neurodegenerative disease investigation (Parkinson's, dementia), PTSD research, and pharmaceutical Phase I/III drug development. MEGIN serves neurology, neurosurgery, oncology, psychiatry, and neuroscience research markets globally.

Universal Brain Inc. develops a medical-grade EEG system designed for precision psychiatry, focusing on objective, brain-based diagnosis and treatment of psychiatric conditions, primarily depression. The company has engineered a next-generation EEG wearable headset that captures event-related potentials (ERPs)—brain responses to cognitive and emotional stimuli—and pairs it with Neurotique™, a proprietary digital interface and AI-driven software algorithm that translates raw EEG data into actionable clinical insights. The platform enables neurotyping: the classification of patients based on functional brain measures derived from EEG, allowing clinicians to identify subtypes of psychiatric disorders and tailor treatment accordingly. Universal Brain's approach addresses the heterogeneity of psychiatric conditions by examining core neural systems including attention, memory, and emotional processing. The system is currently investigational and intended for use in clinical settings to aid treatment decision-making and support psychiatric clinical drug trials. The company's leadership includes a psychiatrist founder/CEO (Kazu Okuda, M.D.) and Chief Scientist with expertise in clinical neuroscience (Greg Hajcak, Ph.D.), indicating strong research-clinical integration. The platform represents a shift toward objective, neurobiological markers rather than symptom-based diagnosis alone.

Lifelines Neuro designs and manufactures portable, mobile video EEG monitoring systems for ambulatory, clinical, and hospital-based neurodiagnostics. The company specializes in electroencephalography (EEG) equipment for diagnosis of epilepsy and other neurological disorders, serving ambulatory EEG service providers, hospitals and healthcare systems, and clinical trial sponsors. Core product lines include Trackit amplifiers (T4A and newer Trackit Solo video EEG system) for lab-quality brain electrical activity recording in diverse settings: in-home, clinic, emergency department, ICU, and EMU environments. Lifelines Neuro partners with StratusEEG, a cloud-based acquisition and review platform accessible 24/7/365 via internet browser, enabling secure HIPAA-ready data storage and physician remote review from any device. The company provides comprehensive support beyond hardware: staffing model consultation, CPT coding reimbursement guidance, workflow optimization, and US-based technical customer support. Founded as a pioneer of ambulatory EEG, Lifelines Neuro has built scalable solutions for both independent service providers launching neurodiagnostic businesses and large healthcare networks expanding patient access to EEG. Clinical trial services include turnkey EEG protocol execution with live data monitoring for drug development pipelines.

Secure Health, Inc. is the exclusive US distributor of Difra Instrumentation vestibular and balance disorder diagnostic equipment. The company specializes in videonystagmography (VNG) systems and caloric irrigation equipment for identifying and diagnosing balance disorders including benign paroxysmal positional vertigo (BPPV), labyrinthitis, vestibular neuronitis, and Meniere's disease. Products include monocular and binocular VNG systems (HeadStar E-Z, HeadStar Full Featured, NysStar), caloric irrigators (AirStar, CoolStar, AquaStar), video Frenzel goggles, and balance assessment platforms. Difra, the manufacturer partner, has over 48 years of experience in vestibular diagnostic technology. The company serves audiologists, otolaryngologists, neurologists, and primary care physicians. VNG testing is supported by insurance and Medicare. Secure Health also provides training through the Better Balance Society, which offers AMA-accredited Category One CME courses on vestibular and balance disorders. The company operates from Fort Wayne, Indiana, and provides installation, training, technical support, and warranty/repair services. Founded by Daniel Scherer, the company focuses on preventing falls in elderly and at-risk patients through early identification and treatment of balance disorders.

Ives EEG Solutions, Inc. manufactures and supplies EEG electrodes and electrode harness systems for clinical, research, and veterinary applications. Founded in 1995, the company specializes in disposable conductive plastic electrodes (DCPE), electrode harnesses, subdermal wire electrodes, and MR/CT-compatible electrode kits. Products are designed for intensive care units (ICUs), epilepsy monitoring units (EMUs), and long-term EEG monitoring. The company emphasizes skin-safe, child-friendly electrode designs to minimize skin breakdown in neonates and sensitive-skin patients. All products are manufactured to support EEG accuracy and cost-effectiveness for hospitals and clinical centers. The company serves hospitals, clinics, research institutions, and veterinary centers globally. Ives EEG Solutions is preferred by EEG technologists for product quality, ease of use, and customer service. The firm also offers free product samples and expert consultation services to support customer needs.

Netech Corporation is a US-based manufacturer of biomedical test equipment and patient simulators for medical device validation and clinical training. Founded over 33 years ago, the company specializes in portable, easy-to-use testing instruments designed for hospital clinical engineering, biomedical maintenance, device manufacturers, and training institutions. Product categories include patient simulators (ECG, EEG, SpO2, pacemaker), defibrillator analyzers, infusion pump analyzers, electrical safety analyzers, pressure meters, and gas flow meters. The MiniSim product line offers compact, modular waveform generators for testing cardiac monitors, EEG recorders, and multi-parameter patient monitoring systems. The EXPMT 2000 External Pacemaker Analyzer is designed for atrial, ventricular, and transcutaneous pacemaker testing. All products are manufactured in the USA. Netech serves clinical engineering departments, biomedical equipment manufacturers, healthcare training centers, and medical device testing laboratories. The company emphasizes quality, reliability, and value in regulatory and performance testing workflows. Equipment is used for device validation, preventive maintenance, troubleshooting, and competency-based training. Netech's offerings support compliance with medical device testing standards and clinical engineering protocols.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.

Electro-Cap International, Inc. is a specialized medical device manufacturer headquartered in Eaton, Ohio, founded in 1988. The company is the world leader in electrode caps for electroencephalography (EEG) and related neurological applications. Their electrode caps serve as diagnostic tools for EEG testing, neurological assessment, neurofeedback protocols, and clinical research. The product line is used across hospitals, neurosurgery departments, psychology clinics, academic universities, and private research laboratories. Electro-Cap caps are designed to enable high-quality signal acquisition for functional brain diagnostics and monitoring. The company maintains a focus on quality and integrity in manufacturing. While specific regulatory certifications and detailed product specifications are not listed on the primary web presence, the company's long operational history and established market position indicate compliance with relevant medical device standards for EEG electrode systems.

Neurotron, Incorporated is a US-based medical device manufacturer established in 1981, headquartered in Aurora, Colorado. The company specializes in the Neurometer® CPT® (Current Perception Threshold), a proprietary neurodiagnostic device for painless, non-invasive sensory nerve fiber testing. The Neurometer® CPT® evaluates small unmyelinated C-fibers, small myelinated Aδ-fibers, and large myelinated Aβ-fibers at any cutaneous site, detecting >90% of sensory nerve fiber types using a standardized, double-blind automated test procedure. FDA-cleared since 1986, the device has been used in over one million tests globally and is supported by more than 800 peer-reviewed publications. The technology quantifies both hyperesthesia and hypoesthesia, monitors nerve regeneration progression, and enables early detection of nerve damage from diabetes, carpal tunnel syndrome, spinal injury, sciatica, radiculopathy, and polyneuropathy. Unlike traditional electrodiagnostic and biopsy procedures, CPT® measurements are unaffected by skin temperature, edema, or electromagnetic interference. The device is portable, battery-powered, painless, non-invasive, and requires no special environmental shielding. Neuval® CPT® software evaluates results against established norms, manages patient records, and generates clinical reports. The company markets through direct sales and an international distributor network across China, Japan, Switzerland, Korea, Benelux, UAE, and Kuwait. Products are manufactured in the USA.

LVIS Corporation is a San Francisco Bay Area–based medical technology company specializing in neural information analysis and EEG diagnostics software. The company develops patented brain-imaging visualization and analysis technologies that decode brain network activity to support neurological disease diagnosis and clinical workflows. LVIS's flagship product is NeuroMatch®, a cloud-based SaaS platform that automates and enhances EEG examination, source localization, and 3D/4D brain visualization. NeuroMatch has received FDA 510(k) clearance (K250239) in the United States and MFDS regulatory clearance in South Korea. The platform addresses critical gaps in neurological healthcare capacity: the shortage of neurologists (1 per 23,259 people), sub-optimal clinical workflows, and surging demand for neurological diagnosis. LVIS is backed by prestigious academic partnerships, including Stanford Byers Center for Biodesign Faculty Fellowship, Stanford StartX incubator, and NVIDIA Inception Program support. The company has received research grants from the Stanford Spectrum Center, LivaNova, and the Epilepsy Foundation. Leadership includes neuroscience and engineering experts; the company was founded by Jin Hyung Lee, PhD. NeuroMatch was named a 2026 Edison Awards finalist. The company operates with headquarters in Palo Alto, California, and additional offices in Gangnam and Daegu, South Korea, serving both US and international markets.

EarliPoint Health is a healthcare technology company specializing in FDA-cleared eye-tracking diagnostic systems for early autism spectrum disorder (ASD) detection and assessment in children ages 16 months through 95 months (7–8 years). The EarliPoint System is a portable, tablet-based device that measures visual attention biomarkers through proprietary algorithms to provide objective, quantifiable data supporting qualified clinicians in ASD diagnosis and treatment progress monitoring. The system captures eye-gaze patterns while children watch video scenes featuring social interactions, analyzing three clinically aligned indices: language, cognition, and social engagement. The company's technology is grounded in decades of developmental research, with clinical validation from large-scale, double-blind studies published in the Journal of the American Medical Association (JAMA) in collaboration with Yale University and Emory University. FDA clearance was obtained via 510(k) submission, confirming substantial equivalence and safety standards. EarliPoint Health addresses critical gaps in early autism diagnosis—the average age of diagnosis in the U.S. exceeds 4 years, well past optimal intervention windows. The system is designed for clinical use in pediatric practices, behavioral health centers, child neurology clinics, and primary care facilities. Administration requires trained staff; interpretation requires qualified clinicians. Results are delivered same-day as detailed diagnostic or progress-tracking reports. The company operates an EarliPoint Network of partner clinics and research institutions including Drexel University Autism Institute, Cincinnati Children's Hospital, University of Nebraska Medical Center, and Easterseals Florida, expanding access across rural and underserved communities.